| Literature DB >> 23401902 |
Abstract
There are several plasma derived von Willebrand factors (vWF) containing factor (FVIII) concentrates that can be used in the treatment of von Willebrand disease (vWD). All concentrates are effective in attaining normal postinfusion levels or of FVIII:C but it is difficult to achieve normalization of the bleeding time even with concentrates containing almost all vWF multimers including those of high molecular weight. Haemate P (Centeon) may be considered as the golden standard concentrate available at present. However, the development of more purified vWF concentrates devoid of FVIII:C is the goal for future development.Entities:
Mesh:
Substances:
Year: 1999 PMID: 23401902 DOI: 10.1046/j.1365-2516.1999.0050s2060.x
Source DB: PubMed Journal: Haemophilia ISSN: 1351-8216 Impact factor: 4.287